Sorted By Test Name - Mayo Medical Laboratories

PROCT
83097
PHD2
61683
prolactin levels >27 ng/mL in the absence of pregnancy and postpartum lactation are indicative of
hyperprolactinemia. Clear symptoms and signs of hyperprolactinemia are often absent in patients with
serum prolactin levels 250 ng/mL are usually associated with
a prolactin-secreting tumor. After initiation of medical therapy of prolactinomas, prolactin levels should
decrease substantially in most patients; in 60% to 80% of patients, normal levels should be reached.
Failure to suppress prolactin levels may indicate tumors resistant to the usual central-acting dopamine
agonist therapies; however, a subset of patients will show tumor shrinkage despite persistent
hyperprolactinemia. Patient who show neither a decrease in prolactin levels nor tumor shrinkage might
require additional therapeutic measures. Resurgent prolactin levels in patients on long-term therapy
indicate, most often, noncompliance with dopaminergic therapy, but can occasionally be an indication of
recurrence.
Reference Values:
Males: 3-13 ng/mL
Females: 3-27 ng/mL
Clinical References: Demers LM, Vance ML: Pituitary function. In Tietz Textbook of Clinical
Chemistry and Molecular Diagnostics. 4th edition. Edited by CA Burtis, ER Ashwood, DE Bruns. St.
Louis, Elsevier Saunders Company, 2006, pp 1976-1981
Prolonged Clot Time Profile
Clinical Information: When coagulation screening tests are performed to verify normal function of
the coagulation system (eg, preoperative, routine examination), they sometimes indicate an abnormality
that may be unexplained (ie, prolonged clotting times). This consultation provides validation of the
prolongation and as comprehensive a work-up as needed to define the abnormality. Possibilities for a
cause of prolongation include: -Factor deficiency(ies), congenital or acquired -Factor inhibitors (including
Coumadin therapy) -Lupus-like anticoagulant -Heparin contamination -Dilution of specimen by
anticoagulant if patient hematocrit is > or =55%
Useful For: Determining cause of prolongation of prothrombin time or activated partial thromboplastin
time Screening for prolonged clotting times and determining the presence of factor deficiency(ies) or
inhibitor (factor-specific, lupus-like, or the presence of heparin)
Interpretation: A interpretive report will be provided.
Reference Values:
An interpretive report will be provided.
Clinical References: Kamal AH, Tefferi A, Pruthi RK: MBBS. How to interpret and pursue an
abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin
Proc 2007 Jul;82:864-873
Prolyl Hydroxylase Domain-2 (PHD2/EGLN1) Gene Sequencing
Clinical Information: Erythrocytosis (increased RBC mass or polycythemia) may be primary, due to
an intrinsic defect of bone marrow stem cells (polycythemia vera: PV), or secondary, in response to
increased erythropoietin (EPO) levels. Secondary erythrocytosis is associated with a number of disorders
including chronic lung disease, chronic increase in carbon monoxide (due to smoking), cyanotic heart
disease, high-altitude living, renal cysts and tumors, hepatoma, and other EPO-secreting tumors. When
extrinsic causes of erythrocytosis are excluded, a heritable cause intrinsic to the RBC or erythrocyte
regulatory mechanisms may be suspected. Mutations in genes coding for hemoglobin
(high-oxygen-affinity hemoglobin variants), hemoglobin-stabilization proteins (2,3 bisphosphoglycerate
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1480